A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Recruiting

Phase 1

KQB168 & PembrolizumabA Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Sponsor:

Kumquat Biosciences Inc.

Code:

NCT06994806

Conditions

Solid Tumor Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

KQB168

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-09. This information was provided to ClinicalTrials.gov by Kumquat Biosciences Inc. on 2026-03-03.